Clinical trial RASolve 301
RASolve 301: Phase 3 Multicenter, Open Label, Randomized Study of RMC-6236 versus Docetaxel in Patients with Previously Treated Locally Advanced or Metastatic RAS(MUT) NSCLC (RMC-6236-301)
| Cancers | |
|---|---|
| Organ | Lung |
| Trial status | Trial open for recruitment |
| Investigator | |
| Trial type |
Interventional with experimental drug
|
| Phase | Trial phase 3 |
| Academic trial | Non |
| Sponsor | Revolution Medicines, Inc. |
| EudraCT Identifier | 2024-518154-16-00 |
| ClinicalTrials.gov | https://clinicaltrials.gov/ct2/show/NCT06881784 |
| Last update |